IBDEI1YV ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,249,0)
 ;;=ABDOMINAL PAIN^1^26
 ;;^UTILITY(U,$J,358.4,250,0)
 ;;=GI^7^26
 ;;^UTILITY(U,$J,358.4,251,0)
 ;;=RESPIRATORY^19^26
 ;;^UTILITY(U,$J,358.4,252,0)
 ;;=ORTHOPEDIC^15^26
 ;;^UTILITY(U,$J,358.4,253,0)
 ;;=PLASTIC SURGERY^16^26
 ;;^UTILITY(U,$J,358.4,254,0)
 ;;=UROLOGY^20^26
 ;;^UTILITY(U,$J,358.4,255,0)
 ;;=PRE-OP EXAM^18^26
 ;;^UTILITY(U,$J,358.4,256,0)
 ;;=METASTATIC CANCER SITES^14^26
 ;;^UTILITY(U,$J,358.4,257,0)
 ;;=NEW PATIENT^3^27
 ;;^UTILITY(U,$J,358.4,258,0)
 ;;=ESTABLISHED PATIENT^1^27
 ;;^UTILITY(U,$J,358.4,259,0)
 ;;=CONSULTATION^2^27
 ;;^UTILITY(U,$J,358.4,260,0)
 ;;=DEMENTIA^1^28
 ;;^UTILITY(U,$J,358.4,261,0)
 ;;=ALCOHOL INDUCED MENTAL DISORDERS^2^28
 ;;^UTILITY(U,$J,358.4,262,0)
 ;;=DRUG INDUCED MENTAL DISORDERS^3^28
 ;;^UTILITY(U,$J,358.4,263,0)
 ;;=OTHER MENTAL/NEURO DISORDERS^4^28
 ;;^UTILITY(U,$J,358.4,264,0)
 ;;=PERSISTENT MENTAL D/O-OTHER CONDITIONS^5^28
 ;;^UTILITY(U,$J,358.4,265,0)
 ;;=TRANSIENT MENTAL D/O-OTHER CONDITIONS^6^28
 ;;^UTILITY(U,$J,358.4,266,0)
 ;;=FUNCTIONAL BRAIN MAPPING^2^29
 ;;^UTILITY(U,$J,358.4,267,0)
 ;;=CNS ASSESSMENTS/TESTS^1^29
 ;;^UTILITY(U,$J,358.4,268,0)
 ;;=NEW PATIENT^2^30
 ;;^UTILITY(U,$J,358.4,269,0)
 ;;=ESTABLISHED PATIENT^1^30
 ;;^UTILITY(U,$J,358.4,270,0)
 ;;=CONSULTATIONS^3^30
 ;;^UTILITY(U,$J,358.4,271,0)
 ;;=POST-OP FOLLOW-UP^4^30
 ;;^UTILITY(U,$J,358.4,272,0)
 ;;=ABRASION w/o INFECTION^1^31
 ;;^UTILITY(U,$J,358.4,273,0)
 ;;=ABRASION w/ INFECTION^2^31
 ;;^UTILITY(U,$J,358.4,274,0)
 ;;=ABSCESS/CELLULITIS^3^31
 ;;^UTILITY(U,$J,358.4,275,0)
 ;;=ACNE^4^31
 ;;^UTILITY(U,$J,358.4,276,0)
 ;;=ALOPEICA^5^31
 ;;^UTILITY(U,$J,358.4,277,0)
 ;;=BURNS^6^31
 ;;^UTILITY(U,$J,358.4,278,0)
 ;;=CANDIDIASIS^7^31
 ;;^UTILITY(U,$J,358.4,279,0)
 ;;=CELLULITIS^8^31
 ;;^UTILITY(U,$J,358.4,280,0)
 ;;=DERMATITIS^9^31
 ;;^UTILITY(U,$J,358.4,281,0)
 ;;=DERMATOPHYTOSIS^10^31
 ;;^UTILITY(U,$J,358.4,282,0)
 ;;=ECZEMA^11^31
 ;;^UTILITY(U,$J,358.4,283,0)
 ;;=EDEMA^12^31
 ;;^UTILITY(U,$J,358.4,284,0)
 ;;=ERYTHEMA^13^31
 ;;^UTILITY(U,$J,358.4,285,0)
 ;;=EXPOSURE TO HEALTH HAZARDS^14^31
 ;;^UTILITY(U,$J,358.4,286,0)
 ;;=FOLLICULITIS^15^31
 ;;^UTILITY(U,$J,358.4,287,0)
 ;;=FURUNCLE^16^31
 ;;^UTILITY(U,$J,358.4,288,0)
 ;;=GRANULOMA^17^31
 ;;^UTILITY(U,$J,358.4,289,0)
 ;;=HERPES^35^31
 ;;^UTILITY(U,$J,358.4,290,0)
 ;;=HISTORY^36^31
 ;;^UTILITY(U,$J,358.4,291,0)
 ;;=ICHTHYOSIS^38^31
 ;;^UTILITY(U,$J,358.4,292,0)
 ;;=INSECT BITE w/o INFECTION^39^31
 ;;^UTILITY(U,$J,358.4,293,0)
 ;;=INSECT BITE w/INFECTION^40^31
 ;;^UTILITY(U,$J,358.4,294,0)
 ;;=KERATOSIS^42^31
 ;;^UTILITY(U,$J,358.4,295,0)
 ;;=LACERATION^44^31
 ;;^UTILITY(U,$J,358.4,296,0)
 ;;=LESION^46^31
 ;;^UTILITY(U,$J,358.4,297,0)
 ;;=LICHENIFICATION^47^31
 ;;^UTILITY(U,$J,358.4,298,0)
 ;;=LUPUS^48^31
 ;;^UTILITY(U,$J,358.4,299,0)
 ;;=MELANOMA^50^31
 ;;^UTILITY(U,$J,358.4,300,0)
 ;;=NAIL DISEASE^53^31
 ;;^UTILITY(U,$J,358.4,301,0)
 ;;=NEOPLASM-BENIGN^54^31
 ;;^UTILITY(U,$J,358.4,302,0)
 ;;=NEOPLASM-IN SITU^56^31
 ;;^UTILITY(U,$J,358.4,303,0)
 ;;=NEOPLASM-OTHER^57^31
 ;;^UTILITY(U,$J,358.4,304,0)
 ;;=NEURODERMATITIS^58^31
 ;;^UTILITY(U,$J,358.4,305,0)
 ;;=PEDICULOSIS^61^31
 ;;^UTILITY(U,$J,358.4,306,0)
 ;;=PITYRIASIS^62^31
 ;;^UTILITY(U,$J,358.4,307,0)
 ;;=PRURITUS^63^31
 ;;^UTILITY(U,$J,358.4,308,0)
 ;;=PSORIASIS^64^31
 ;;^UTILITY(U,$J,358.4,309,0)
 ;;=STASIS^66^31
 ;;^UTILITY(U,$J,358.4,310,0)
 ;;=ULCER^68^31
 ;;^UTILITY(U,$J,358.4,311,0)
 ;;=ULCER-LOWER EXTREMITY^69^31
 ;;^UTILITY(U,$J,358.4,312,0)
 ;;=URTICARIA^70^31
 ;;^UTILITY(U,$J,358.4,313,0)
 ;;=VARICOSE VEINS^71^31
 ;;^UTILITY(U,$J,358.4,314,0)
 ;;=WOUND^73^31
